Funding profile · Lab automation

Opentrons Labworks

Eight Form D notices, $303.4 million sold, one $209 million round led by SoftBank Vision Fund 2 in 2021, then a four year gap and a 2025 filing with two investors and a new board.

$303.4MSold across eight Form D filings, 2017 to 2025
$209.0MSold in the Sep 2021 round, announced as $200M
$1.8BValuation reported at that round, up from $90M a year earlier
$20.1MSold of $56.6M offered in the Dec 2025 filing, 2 investors

Data as of September 22, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
2014 Kickstarter, first machine $126,000 237 backers Independent
Mar 2017 First Form D $7,159,685 34 Form D
Mar 2018 Seed, announced $10M announced; $10,549,999 filed Sep 2018 Khosla Ventures, Lerer Hippeau, Y Combinator Continuity; 23 on the filing Form D + press
Nov 2019 Form D $2,250,000 17 Form D
May 2020 SPV: Opentrons, A Series of Assure Labs 2020, LLC $52,968 7, minimum $2,500 each Form D
Aug 2020 Form D, equity $20,599,371 32 Form D
Nov 2020 Form D, option to acquire $8,731,153 of $9.0M 9 Form D
Feb 2021 Form D, option to acquire $25,020,000 17 Form D
Sep 2021 Series C $200M announced; $209,019,995 filed of $234,019,991 SoftBank Vision Fund 2 lead, Khosla Ventures; also Sands Capital, SOSV, Y Combinator; 24 on the filing Form D + release
Dec 2025 Form D, equity $20,118,247 of $56,618,247 2 Form D
2017 to 2026 Federal purchase orders, not investment $559,527.51 25 prime contracts, six agencies USAspending

What the filings show

Opentrons Labworks, Inc. · Form D · filed Dec 5, 2025

First sale
Nov 20, 2025
Offered
$56,618,247 equity
Sold
$20,118,247 · $36,500,000 remaining
Investors
2 · average about $10,059,124
Exemption
Rule 506(b)
Related persons
James Atwood (executive officer, director); Leslie Mitchell, Myrtle Potter, Alex Morgan, Juan Franck (directors)
Address
45-18 Court Square West, Long Island City, NY
Filing
SEC EDGAR, CIK 0001701598

Opentrons Labworks, Inc. · Form D · filed Sep 23, 2021

First sale
Sep 20, 2021
Offered
$234,019,991 equity and options to acquire
Sold
$209,019,995 · $24,999,996 remaining
Investors
24 · average about $8,709,166
Exemption
Rule 506(b)
Related persons
Jonathan Brennan-Badal, Chiu Chau (executive officers, directors); Greg Greeley (executive officer); Sven Strohband, Eric Hippeau, Myrtle Potter (directors)
Filing
SEC EDGAR, CIK 0001701598

Opentrons, A Series of Assure Labs 2020, LLC · Form D · filed May 18, 2020

First sale
May 14, 2020
Type
Pooled investment fund, single company vehicle
Sold
$52,968 of $52,968
Investors
7 · average about $7,567 · minimum $2,500
Expenses
$3,294 of gross proceeds used for the offering
Exemptions
Rule 506(b); Investment Company Act 3(c)(1)
Related persons
Assure Fund Management II LLC; Richard Thoms; Jeremy Neilson
Filing
SEC EDGAR, CIK 0001812037

Reading the filings

  1. The filed number beat the announced number.The press release said $200 million. The Form D filed the same day reports $209,019,995 sold of $234,019,991 offered, from 24 investors, about $8.71 million each. The round closed larger than the number in the headline.
  2. Reported lifetime funding matched only part of the record.Fierce Biotech wrote in 2021 that the Series C far outpaced a previous tally of about $40 million in lifetime financing. The Form Ds through August 2020 total $40,559,055. The next two filings add $33,751,153, bringing the pre Series C total to $74,310,208. Both report options to acquire rather than equity, which fits convertible paper counted at conversion.
  3. Angels came in through a Utah vehicle.In May 2020 a single company series of Assure Labs 2020, LLC raised $52,968 from 7 investors with a $2,500 minimum, and paid $3,294 as offering expenses, 6.2 percent of the raise.
  4. The December 2025 filing is a different kind of round.Two investors, $20,118,247 sold, $36,500,000 still on offer, first sale November 20, 2025. Two checks of about $10 million each after a four year gap read as existing holders, not a new lead. Current releases name SoftBank and Khosla Ventures as backers.
  5. The board turned over almost completely.The 2021 filing names Brennan-Badal, Chau, Greeley, Strohband, Hippeau and Potter. The 2025 filing names Atwood, Mitchell, Potter, Morgan and Franck. Only Myrtle Potter appears on both. James Atwood had taken over as chief executive in July 2025, six months before the company said so publicly.
  6. The address moves track the business.68 Jay Street in Brooklyn in 2017, 285 13th Street in Manhattan in 2021, and 45-18 Court Square West in Long Island City in 2025, the same site where Pandemic Response Lab was wound down at the end of 2022.

Commercial signals

Signal Detail Source type
Federal demand 25 federal prime contracts, $559,527.51, 2017 to 2026, across six agencies. Resellers billed separately, including $124,200 for a Flex V2 robot in July 2026. Public record
Diagnostics exit Pandemic Response Lab wound down Dec 31, 2022. State labor filings recorded 185 job losses at the Long Island City plant. Independent
Partner BD collaboration announced Oct 8, 2025 to integrate the Flex with the BD Rhapsody single cell system. Terms not disclosed. Partner-stated
Installed base More than 10,000 systems, every top 20 US research university, 14 of the top 15 global biopharma companies. Company-stated
Revenue Revenue range reported as Decline to Disclose on all eight Form D filings. Public record
Regulatory No FDA 510(k), no PMA, and no listing on the FDA molecular SARS-CoV-2 emergency use authorization page, checked Sep 23, 2026. Not found

What to watch

  • An amended Form D on the December 2025 offering, which would show whether the remaining $36,500,000 was taken up.
  • Whether a priced round follows, and at what valuation against the $1.8 billion reported in 2021.
  • Any disclosure of revenue or unit volumes, which the company has withheld on every filing.
  • Whether the four new directors named in 2025 point to a new lead investor or to a restructuring among existing holders.

The Opentrons story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • BillionToOne: Shared investor: Assure Fund Management. A Menlo Park laboratory that counts individual DNA molecules in blood, first to tell a pregnant patient whether her fetus is at risk for a recessive disease, now to read
  • Volumetric Biotechnologies: Shared investor: Assure Fund Management. A Rice University spin-out that printed a hydrogel air sac able to oxygenate flowing blood, sold to 3D Systems in 2021 for a headline $400 million, and watched the
  • Papa: Shared investor: Softbank Vision Fund. A national network of vetted companions who visit older adults at home, paid for by Medicare Advantage and Medicaid plans
  • Medcrypt: Shared investor: Assure Fund Management. A San Diego company that sells device makers the cryptography, vulnerability tracking and regulatory paperwork the FDA now demands before a connected device reaches the

Sources

  1. Public recordEight Form D filings, Opentrons Labworks Inc., CIK 0001701598SEC EDGAR · Mar 22, 2017 to Dec 5, 2025
  2. Public recordForm D, Opentrons, A Series of Assure Labs 2020, LLC, CIK 0001812037SEC EDGAR · May 18, 2020
  3. Public recordFederal prime contract awards to Opentrons Labworks Inc.USAspending.gov · queried Sep 23, 2026
  4. Public recordIn Vitro Diagnostics EUAs for SARS-CoV-2FDA · checked Sep 23, 2026
  5. IndependentLab platform Opentrons closes $200M series CFierce Biotech, Andrea Park · Sep 23, 2021
  6. IndependentOpentrons opts for $200m series C roundGlobal Venturing · Sep 24, 2021
  7. IndependentCity Covid testing lab will close, lay off 185 workersCrain’s New York Business · Dec 6, 2022
  8. CompanyOpentrons Announces $200 Million Series C RoundBusiness Wire · Sep 23, 2021
  9. CompanyJames Atwood Named Chief Executive OfficerBusiness Wire · Jan 29, 2026
  10. PartnerBD and Opentrons Collaborate on Single-Cell MultiomicsBD newsroom · Oct 8, 2025

Compiled from SEC, USAspending and FDA public records and published reports as of September 22, 2026. Form D notices report offerings under Regulation D; amounts reflect the filing date and may not capture later sales. Healthcare Venture Capital Fund holds no position in Opentrons Labworks. This page is not an offer to sell or a recommendation to buy any security.